Harnessing the regenerative
Power of fat, the largest source of stem cells.
1st Publication
Company
Management Team
Advisors
Sayenza Biosciences
Sayenza Bio is a leading clinical stage biotechnology company committed to improving patient lives by harnessing the regenerative power of fat, the body’s largest source of stem cells, for limitless aesthetic and regenerative medicine applications.
At Sayenza, our passionate, doctor-driven team unites cutting-edge scientific innovation with vast commercial expertise, propelling us towards transformative breakthroughs in healthcare.
HCP Led Proven Leadership Team
Derek Banyard
MD, MS, MBA
Co-founder, CEO
Sahil
Nock
Chief Commercial Officer
Jered Haun
PhD
Co-founder, Engineering Consultant
Alan Widgero
MBBCh, MMed
Co-founder, Clinical Consultant
Adam
Mathis
Co-founder, CEO
World Class Advisors Across Key Areas
Problem
Product
Science
Comparable cell counts & viability. Superior enrichment of key stem cell populations.
*Compared to standard manual processing
Traction
Aug
2016
$50K Grant
Aug
2016
$25K Grant
Mar
2019
PCT Filed
Jun
2020
Company Founded
Jun
2020
C18 – UCI Incubator
Jan
2021
3er place $15k
Apr
2021
Converted (US/EU)
Dec
2021
Grand Prize $25K
Apr
2022
LaunchPad Accelerator
Aug
2022
2nd Pub Published
Apr
2022
Pre-Seed $330k
Mar
2023
Provisional Patent Filed
Mar
2023
Investment Opportunity
Market
Get In Touch With Us Today
For any inquiries or information regarding our innovative regenerative medicine and immunotherapy technologies, please contact us through the provided form or emal.